Blythe Demello
Critical Care Medicine · Tucson, AZNPI 1558002675
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 277 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,697, 3.0 times the $892 reported in 2023. Among critical care medicine clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 277 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$754
- Pfizer$634
- Novartis$504
- Merck$433
- GSK$272
- AbbVie$265
- plus $3K from 46 others
What the payments were for
- Food & beverage$5,90295%
- Education$2815%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,183 in reported general payments places this provider in the 90th percentile of 175 critical care medicine providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 31 | $623,048 |
| XtandiEnzalutamide | 24 | $285,399 |
| JakafiRuxolitinib Phosphate | 12 | $207,732 |
| BrukinsaZanubrutinib | 11 | $167,090 |
| ProliaDenosumab | 51 | $88,268 |
| XareltoRivaroxaban | 45 | $57,034 |
| XgevaDenosumab | 16 | $52,232 |
| EliquisApixaban | 57 | $41,104 |
| Letrozole | 71 | $2,233 |
| Anastrozole | 67 | $1,551 |
| Oxycodone Hcl | 17 | $428 |
| Mirtazapine | 12 | $312 |
| Hydroxyurea | 23 | $302 |
| Gabapentin | 16 | $220 |
| Ondansetron OdtOndansetron | 16 | $174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $264 | $623,04831 claims |
| Astellas Pharma US IncXtandi | $63 | $285,39924 claims |
| Incyte CorporationJakafi | $151 | $207,73212 claims |
| Beigene USA, Inc.Brukinsa | $17 | $167,09011 claims |
| AmgenProlia, Xgeva | $34 | $140,50067 claims |
| Johnson & JohnsonXarelto | $179 | $57,03445 claims |
| PfizerEliquis | $634 | $41,10457 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $40 | $15713 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $18 | $14316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 175 critical care medicine providers in Arizona.
Other critical care medicine in Tucson
- Wesley CookTucson$3K
- Nikolay AzarovTucson$2K
- Antara MallampalliTucson$2K
- Joel LuceroTucson$1K
- Naomi HabibPhoenix$298K
- Heather PrzybylPhoenix$126K
- Douglas MapelPrescott$125K
- Akshay MuralidharScottsdale$44K
- Syed ShahryarPhoenix$20K
- Rodrigo Cartin-CebaScottsdale$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.